Try our Advanced Search for more refined results
March 17, 2016
New York University v. Galderma Laboratories, Inc.
Case Number:
16-817
Court:
Nature of Suit:
4190 CONTRACT-Other Contract Action
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
April 27, 2017
2nd Circ. Reverses NYU's $3.5M Award In Drug License Spat
The Second Circuit on Wednesday reversed a $3.5 million summary judgment in favor of New York University in a breach of contract dispute between the school and drugmaker Galderma Laboratories, finding that the district court had no basis to conclude the rosacea drug Oracea was or wasn't a licensed product.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login